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OBJECTIVE: To analyse the cost-minimization of Everolimus
in comparison with Sirolimus for immunosuppression in kidney
transplantation. METHODS: A cost-minimization analysis from
the Brazilian National Health system perspective, with a time
horizon of seven years were conducted. A decision tree with a
Markov chain considering the probabilities of graft loss or main-
tenance through health states related to presence or absence of
any relevant health event, were performed. Study comparators
examined were Everolimus (EVE) and Sirolimus (SLR). The clini-
cal aspects regarding beneﬁts and probabilities of transition data
were extract from meta-analysis of published randomized clinical
trials for the alternatives. The analysis is based on Brazilian
current clinical practice. Treatment costs were collected from
public reimbursement list. Costs and beneﬁts were validated by
a panel of Brazilian specialists from Ministry of Health through
the Delphi technique. The discounting rate was 5% for costs
and beneﬁts, the results were converted in US Dollars (R$1.8/
USD$1.00). A one-way sensitivity analysis was performed.
RESULTS: Patients using Everolimus get the lowest total cost per
treatment (EVE = $15,347.58USD; SLR = $29,959.6USD). The
sensitivity analysis on costs variables in an interval of 80%,
was robust with the base analysis. CONCLUSION: Everolimus
is a cost-saving alternative for immunossuppresion in kidney
transplantation compared to Sirolimus in the perspective of
Brazilian Public Health System.
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OBJECTIVE: Current National Institute for Health and Clinical
Excellence (NICE) Clinical Guidelines on managing anemia in
patients with chronic kidney disease (CKD) state that there is
no evidence to differentiate between erythropoiesis-stimulating
agents in terms of efﬁcacy. Cost minimization analysis (CMA) is,
therefore, an appropriate health economic approach in this
therapy area. This CMA of epoetin zeta (Retacrit®), a biosimilar
agent of epoetin alfa, versus current standard treatments was
conducted from the perspective of NHS Scotland. METHODS: A
CMA of intravenous and subcutaneous epoetin, published in the
full NICE Clinical Guidelines, was used as a framework for this
cost analysis of epoetin zeta, the reference product epoetin alfa,
epoetin beta and darbepoetin alfa. In both the NICE and this
analysis, it was assumed that the cost difference of epoetin and
iron administration would be negligible. Licensed epoetin doses
were incorporated in this analysis. RESULTS: This analysis dem-
onstrates that epoetin zeta minimizes costs for treating anemia
associated with CKD when compared with the reference product,
epoetin alfa. The cost of epoetin zeta for a hemodialysis patient
is £59.39/week (hemoglobin correction phase) and £29.70–
£118.79/week (hemoglobinmaintenance phase), based on a 70 kg
patient. The corresponding cost for a patient treated with epoetin
alfa is £67.32/week and £33.66–£134.64/week. The low drug
acquisition cost for epoetin zeta could lead to potential cost
savings. CONCLUSION: CMA is an appropriate approach for
managing anemia in peoplewithCKD.This analysis demonstrates
that the biosimilar product, epoetin zeta, minimizes treatment
costs and would be of beneﬁt to patients and NHS Scotland.
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OBJECTIVE: Using data from a large, multicenter, double-blind,
phase III clinical trial designed to evaluate the efﬁcacy and safety
of a vaccine intended to reduce the incidence of S. aureus infec-
tion in adults with ESRD receiving hemodialysis, we examined
inpatient costs, inpatient days, and mortality associated with
S. aureus bloodstream and non-bloodstream infections.
METHODS: Inpatient bills were obtained for patients hospital-
ized with S. aureus infection. Clinical and laboratory data were
recorded in the report form. Hospital charges were converted to
costs using department-level cost-to-charge ratios derived from
each hospital’s Annual Medicare Cost Report. Statistics were
used to report 12-week economic and clinical outcomes. Among
patients with S. aureus bacteremia, those with additional sites of
S. aureus infection were compared to those without using gener-
alized linear regression models adjusting for confounders.
RESULTS: Among 89 patients hospitalized with S. aureus bac-
teremia, the mean inpatient cost was $19,454 (median: $13,011)
over 12 weeks, representing an average of 11.9 inpatient days.
Among 70 patients hospitalized with non-bloodstream S. aureus
infections, the mean 12-week cost was $19,222 (median:
$13,106) across a mean of 11.3 inpatient days. Twelve-week
mortality was 20.2% for patients with S. aureus bacteremia and
15.7% for patients with non-bloodstream S.aureus infections.
When adjusting for baseline demographics and medical history
among patients with S. aureus bacteremia, those who experi-
enced additional sites of S. aureus infection (n = 33) incurred
1.43-fold higher 12-week inpatients costs compared to those
without sites of S. aureus infection (p = 0.0497). Inpatient days
(13.5 vs. 11.0; P = 0.3154) and 12-week mortality (15.15% vs.
23.21%; P = 0.6569) did not signiﬁcantly differ between S.
aureus bacteremia patients with and without additional sites of
S. aureus infection. CONCLUSION: S. aureus infections impose
considerable economic burden in ESRD patients undergoing
hemodialysis. The existence of additional sites of S. aureus
infection among patients with S. aureus bacteremia increases
inpatient costs.
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OBJECTIVE: Angiogenesis inhibitor therapies (oral sunitinib or
sorafenib, or IV bevacizumab off-label) are currently available as
treatments for RCC patients. However, IV therapy may impose
additional burdens for patients such as time lost in travel to
treatment facilities, infection risk from IV catheters and increased
costs. The potential incremental cost by resource use category
associated with IV vs. oral administration of selected angiogen-
esis inhibitor therapies for the treatment of RCC was evaluated.
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METHODS: Patients with 2RCC claims (ICD-9 189.0, 198.0)
receiving sunitinib (n = 244), sorafenib (n = 234) or bevacizumab
(n = 106) were identiﬁed from a large US commercial health
insurance claims database covering over 39 million people
between January 2002–December 2006. Patients were observed
from their ﬁrst angiogenesis inhibitor therapy claim until the last
treatment date. Inpatient, outpatient and pharmacy costs (actual
payments made by health plans) were calculated on a per-patient
per-month (PPPM) basis over the treatment period with costs for
the study drugs reported separately. RESULTS: PPPM costs for
bevacizumab were $5130 higher than PPPM costs for sorafenib
and $3,261 higher than PPPM costs for sunitinib. Additionally,
bevacizumab drug and IV administration costs accounted for
51% of the outpatient costs for those patients. Excluding drug
and administration costs, bevacizumab patients still incurred
higher PPPM outpatient services costs of $3956, compared with
patients receiving sunitinib or sorafenib at $2913 and $2230
respectively. Monthly costs for inpatient services were also higher
for bevacizumab patients ($2467) vs. sunitinib ($1716) and sor-
afenib ($1082) patients. CONCLUSION: RCC patients treated
with bevacizumab incur an additional $39,132–$61,560 total
medical cost increase per patient per year compared to those
treated with sunitinib or sorafenib. The development of more
tolerable and efﬁcacious oral angiogenesis inhibitor therapies
may result in additional cost savings to patients and health care
payers over IV therapies.
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OBJECTIVE: Evidence has shown important therapeutic
outcome differences between dutasteride and ﬁnasteride. The
objective of this study was to assess the differences in economic
costs between these two pharmacologic treatment options within
the ﬁrst year of initiating therapy for Medicare-aged men with
benign prostatic hyperplasia (BPH) from a managed care per-
spective. METHODS: A retrospective analysis of medical and
pharmacy claims was conducted using the Ingenix Lab Rx pro-
prietary research database within a 3-year period from July 1,
2003 to June 30, 2006. Male patients aged  65 years with a
diagnosis of BPH treated with either dutasteride or ﬁnasteride
were identiﬁed. To minimize potential biases that arose from
differential treatment selection, propensity-score-matching
methods were used to identify ﬁnasteride and dutasteride
patients who were similar in terms of their Charlson Comorbid-
ity Index score, Thomson Medstat staging and other background
covariates. Average monthly medical costs were deﬁned as the
total amount charged for BPH-speciﬁc physician visits, inpatient
hospitalizations, outpatient hospital care, emergency department
visits and other ancillary medical services during the follow-up
period for each patient. RESULTS: The matched sample included
a total of 4498 patients. Demographics were comparable
between the two treatment groups with a mean age of 73.6 years.
Patients taking dutasteride had signiﬁcantly lower medical
resource utilization costs per month compared to ﬁnasteride-
treated patients ($122 vs. $173, P < 0.001). The absolute differ-
ence in cost is $51 less per month with dutasteride use. The lower
costs associated with dutasteride appears to be due to the lower
inpatient hospitalization costs ($35.78 vs. $72.29 per month
with ﬁnasteride). CONCLUSION: Medicare-aged patients
treated with dutasteride consumed signiﬁcantly lower medical
resources due to lower inpatient hospitalization expenditure,
showing cost savings of $51 per month per treated patient.
This study supports the growing body of real-world evidence
indicating the clinical and economic beneﬁts associated with
dutasteride.
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OBJECTIVE: To evaluate cost-utility of sevelamer versus
calcium-based phosphate binders (CaPB) in different patient
cohorts and for different dialysis modalities. METHODS: Sys-
tematic literature review was conducted with only studies report-
ing mortality considered. Subgroup analyses were carried out
based on results from one trial (DCOR). Costs of dialysis were
obtained from a recent UK-based study; dosage of drugs was
taken from the DCOR trial, and unit prices from the British
National Formulary; costs were expressed in 2007; utilities
were sourced from the literature. Markov model was developed
for analysis. RESULTS: Six RCTs of sevelamer versus CaPB
reporting all-cause mortality were identiﬁed. No signiﬁcance was
found in meta-analysis: RR = 0.83 [95%CI:0.56–1.17]; differ-
ence in cardiovascular mortality was not signiﬁcant, based on
three RCTs: 0.94 [0.76–1.17]. In the general haemodialysed
population sevelamer cost 6491 more than CaPB after ten
years of treatment, regardless of dialysis modality. In the 65 and
older population, cost of sevelamer was 30,293 higher, while
efﬁcacy was 0.52 QALYs greater; ICER = 58,405. In patients
on peritoneal dialysis, sevelamer cost 17,837 more than CaPB,
with identical efﬁcacy; ICER = 34,389. In patients treated for
at least two years, sevelamer cost 27,266 more, while its
efﬁcacy was 0.41 QALYs higher; ICER = 65,782. In the
65 + population treated for at least two years, cost of sevelamer
was 38,378 higher, while efﬁcacy was 0.70 QALYs greater;
ICER = 55,182. Acceptability curves revealed that probability
of sevelamer being cost-effective at 20,000/QALY ranged 1.2–
13.4%; EVPI was 17–194. With the costs of dialysis excluded,
ICER ranged from 11,944 to 22,543; for all scenarios ICER
diminished with longer time horizons. CONCLUSION: Seve-
lamer is not likely cost-effective, but in the older population it is
more cost-effective in patients on peritoneal dialysis than on
haemodialysis. ICER is relatively high for subgroups, mainly due
to the high cost of dialysis of patients who live longer due to
sevelamer.
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OBJECTIVE: This study assessed costs related to anemia man-
agement in a reference dialysis center. The study also explored
the potential beneﬁt of efﬁciency improvement and costs reduc-
tion with the use of C.E.R.A., a novel continuous erythropoietin
receptor activator that is effective for treating anemia with a once
monthly injection. METHODS: This study was conducted at the
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